Please assess the completion status of the following clinical trial:

Trial Title: Comparison of the Safety and Efficacy of Intravenous Iron Versus Oral Iron in the Treatment of Anemia Secondary to Heavy Uterine Bleeding

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female subjects \>/= 18 years of age~* History of Heavy uterine bleeding~* Hgb \</= 11~* Practicing acceptable birth control~* Demonstrate ability to understand and comply with protocol~Exclusion Criteria:~* Known Hypersensitivity to oral or IV iron~* Anemia other than iron deficiency anemia~* Iron storage disorders~* Initiation of treatment that may effect degree of heavy uterine bleeding~* Anticipated need for surgery~* Severe psychiatric disorder~* Active infection~* Positive Pregnancy test~* Known Hep B or C or Active Hepatitis~* Received investigational Drug within 30 days~* Alcohol or drug abuse

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ferric Carboxymaltose (FCM) (Type: EXPERIMENTAL): Maximum of 1,000 mg of iron as IV FCM given at weekly intervals until the individual's calculated cumulative dose has been reached or a maximum of 2,500 mg has been administered
- Ferrous Sulfate tablets (Type: ACTIVE_COMPARATOR): 325 mg tablets TID on Days 0 through Day 42

Based on this trial design, predict the completion outcome and termination type (if applicable).